EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical outcomes of lutetium-177–PSMA-617 in a racially diverse cohort of patients with metastatic castration-resistant prostate cancer

Margo Brooke Gerke iD, Akshay Bedmutha, Angelo Marra iD, Yuan Liu iD, Jacqueline T Brown, Bassel Nazha, Jacob E Berchuck, Ravi Bharat Parikh, Shahid Ahmed, Jordan Alana Ciuro, Caitlin Hartman, Greta Russler McClintock und 6 weitere

The Oncologist · 05.02.2026 · 31 (3)

DOI: 10.1093/oncolo/oyag022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 03.02.2026. Verfasst von Margo Brooke Gerke und 17 weiteren Autor:innen. Beteiligte Einrichtung: Emory University School of Medicine, Atlanta, GA 30322, United States. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Lutetium, Dipeptides, Heterocyclic Compounds, 1-Ring. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institutes of Health/the National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lutetium-177 (177Lu)–PSMA-617 is a beta-emitting radioligand approved for treatment of metastatic castration-resistant prostate cancer (mCRPC), despite the underrepresentation of Black patients in pivotal trials. We analyzed outcomes of 177Lu-PSMA-617 in a racially diverse cohort.

Methods

Retrospective analysis of patients with mCRPC treated with 177Lu-PSMA-617 was conducted at the Emory Winship Cancer Institute. Primary outcomes assessed were progression-free survival (PFS), overall survival (OS), and prostate-specific antigen (PSA) reduction ≥50% (PSA50). Cox proportional hazard models were used for univariate and multivariate OS and PFS, and logistic regression was used for PSA50 analysis.

Results

Among 163 patients treated with 177Lu–PSMA-617, 97 (59.5%) self-identified as White or other racial groups and 66 (40.5%) self-identified as Black. On univariate analysis, Black patients had comparable OS, PFS, and PSA50 responses to non-Black patients, with a trend toward improved outcomes (OS HR: 0.82, P = .446; PFS HR 0.92, P = .655; PSA50 OR = 1.79, P = .088). Multivariate analysis demonstrated a non-significant prolonged PFS and reduction in mortality risk for Black patients (PFS HR: 0.65, P = .106; OS: HR 0.59, HR P-value .081). The odds of a PSA50 response were 2.45 times higher for Black patients (OR = 2.45, P = .027).

Conclusions

In our racially diverse cohort of patients with mCRPC, Black patients had PFS and OS comparable to non-Black patients, although wide confidence intervals limit definitive conclusions. Black patients had a significantly greater odds of achieving a PSA50 response. Our findings suggest efficacy of 177Lu-PSMA-617 among Black patients in real-world settings and underscore the importance of improved representation in prospective studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantLutetiumDipeptidesHeterocyclic Compounds, 1-RingRadioisotopesHumansMaleAgedRetrospective StudiesMiddle AgedProstate-Specific AntigenAged, 80 and overNeoplasm MetastasisTreatment Outcome

Stichwörter der Autor:innen

lutetium-177–PSMA-617metastatic castration-resistant prostate cancerracial disparitiesradioligand therapyreal-world outcomes

Substanzen

LutetiumDipeptidesHeterocyclic Compounds, 1-RingLutetium-177RadioisotopesProstate-Specific AntigenPSMA-617

Autor:innen und Institutionen

  • Emory University School of Medicine, Atlanta, GA 30322, United States.
  • Department of Radiology and Imaging Sciences, Division of Nuclear Medicine and Molecular Imaging, Emory University, Atlanta, GA 30322, United States.
  • Biostatistics Shared Resource, Winship Cancer Institute, Emory University, Atlanta, GA 30322, United States.
  • Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA 30322, United States.
  • Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, United States.
  • Emory Winship Cancer Institute, Atlanta, GA 30322, United States.

ORCID-Profile: Margo Brooke Gerke, Angelo Marra, Yuan Liu, Mehmet Asim Bilen

Förderung

  • National Institutes of Health/the National Cancer Institute

Zitieren

APA

Gerke, M. B., Bedmutha, A., Marra, A., Liu, Y., Brown, J. T., Nazha, B., Berchuck, J. E., Parikh, R. B., Ahmed, S., Ciuro, J. A., Hartman, C., McClintock, G. R., Caulfield, S., Kucuk, O., Carthon, B. C., Schuster, D. M., Muzahir, S., & Bilen, M. A. (2026). Clinical outcomes of lutetium-177–PSMA-617 in a racially diverse cohort of patients with metastatic castration-resistant prostate cancer. The Oncologist, 31(3). https://doi.org/10.1093/oncolo/oyag022

Vancouver

Gerke MB, Bedmutha A, Marra A, Liu Y, Brown JT, Nazha B, et al. Clinical outcomes of lutetium-177–PSMA-617 in a racially diverse cohort of patients with metastatic castration-resistant prostate cancer. The Oncologist. 2026;31(3). doi:10.1093/oncolo/oyag022

BibTeX
@article{Gerke2026,
  author = {Gerke, Margo Brooke and Bedmutha, Akshay and Marra, Angelo and Liu, Yuan and Brown, Jacqueline T and Nazha, Bassel and Berchuck, Jacob E and Parikh, Ravi Bharat and Ahmed, Shahid and Ciuro, Jordan Alana and Hartman, Caitlin and McClintock, Greta Russler and Caulfield, Sarah and Kucuk, Omer and Carthon, Bradley Curtis and Schuster, David M and Muzahir, Saima and Bilen, Mehmet Asim},
  title = {Clinical outcomes of lutetium-177–PSMA-617 in a racially diverse cohort of patients with metastatic castration-resistant prostate cancer},
  journal = {The Oncologist},
  year = {2026},
  volume = {31},
  number = {3},
  doi = {10.1093/oncolo/oyag022}
}
Kostenlos starten →